# Comprehensive clinical analysis of gastric-type endocervical adenocarcinoma: a real-world multicenter study

## TL;DR

This study analyzed 124 cases of a rare cervical cancer type, finding that older age and advanced stage worsen outcomes, while surgery and chemotherapy improve survival.

## Contribution

The study provides real-world clinical insights and identifies prognostic factors for gastric-type endocervical adenocarcinoma.

## Key findings

- 5-year overall survival was 46.1%, indicating an aggressive disease with poor prognosis.
- Older age and advanced stage were significant risk factors for worse survival.
- Surgery and multiple chemotherapy cycles were associated with improved survival outcomes.

## Abstract

Gastric-type endocervical adenocarcinoma (G-EAC) is a rare malignancy, and its clinicopathological characteristics remain poorly defined. This study aimed to evaluate the real-world features, treatment patterns, and outcomes of patients with G-EAC.

Clinical data from 124 patients diagnosed with G-EAC between 2012 and 2024 across four tertiary hospitals in China were retrospectively analyzed. Clinicopathological features, therapeutic approaches, and survival outcomes were assessed. Overall survival (OS) was the primary endpoint. Kaplan–Meier and Cox regression analyses were performed to identify prognostic factors.

The median diagnostic age was 55 years (range, 33–82). At presentation, 62.1% of patients had invasion or metastasis, most commonly lymphovascular (47.6%). Surgery was performed in 81.5% of cases, and 84.7% received chemotherapy, primarily platinum-based (81.5%). Radiotherapy was administered to 69.4%. The 1-, 3-, and 5-year OS rates were 78.6%, 54.8%, and 46.1%, respectively. Older age (≥65 years; HR, 4.71; 95% CI, 1.52–14.58; p = 0.0071) and advanced stage (p < 0.05) predicted poorer OS, while surgery (HR, 0.10; 95% CI, 0.02–0.43; p = 0.0019) and multiple chemotherapy cycles (p < 0.05) were independent protective factors.

G-EAC exhibits aggressive behavior and unfavorable prognosis, with a 5-year OS of 46.1%. Multimodal treatment, particularly surgery combined with chemotherapy, remains the cornerstone of management and may improve survival. Prospective multicenter studies are warranted to further define optimal therapeutic strategies for this rare entity.